Capricor Therapeutics Inc (CAPR)
6.78
+0.02
(+0.30%)
USD |
NASDAQ |
Mar 28, 16:00
6.78
0.00 (0.00%)
After-Hours: 16:40
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 212.89M |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 64.48% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 7.210 |
Price to Book Value | 9.419 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 98.99% |
Profile
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine. |
URL | https://www.capricor.com |
Investor Relations URL | N/A |
HQ State/Province | California |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Feb. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine. |
URL | https://www.capricor.com |
Investor Relations URL | N/A |
HQ State/Province | California |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2024 (est.) |
Last Earnings Release | Feb. 29, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |